Detalles de la búsqueda
1.
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Breast Cancer Res
; 20(1): 79, 2018 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30053900
2.
The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Acta Oncol
; 57(1): 44-50, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202609
3.
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Breast Cancer Res Treat
; 159(1): 71-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27447876
4.
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
BMC Cancer
; 14: 177, 2014 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24625003
5.
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
PLoS One
; 19(5): e0302129, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38753705
6.
Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
J Clin Oncol
; 39(2): 126-135, 2021 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33108242
7.
Development of Gene Expression-Based Biomarkers on the nCounter® Platform for Immuno-Oncology Applications.
Methods Mol Biol
; 2055: 273-300, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31502157
8.
Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Clin Breast Cancer
; 20(4): e423-e432, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253134
9.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
NPJ Breast Cancer
; 6: 7, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140564
10.
Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
J Immunother Cancer
; 7(1): 76, 2019 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30876461
11.
A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
J Immunother Cancer
; 7(1): 15, 2019 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30665466
12.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol
; 4(4): 545-553, 2018 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29450494
13.
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
J Clin Oncol
; 36(8): 735-740, 2018 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29369732
14.
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
J Natl Cancer Inst
; 109(2)2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27794124
15.
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Clin Cancer Res
; 22(3): 560-6, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26152740
16.
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
J Clin Oncol
; 33(8): 916-22, 2015 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25332252
17.
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
BMC Med Genomics
; 8: 54, 2015 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26297356
18.
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Curr Med Res Opin
; 31(6): 1129-37, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25851308
19.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Clin Cancer Res
; 20(5): 1298-305, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24520097
20.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
J Natl Cancer Inst
; 105(19): 1504-11, 2013 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-24029245